Merck & Co Inc
Research Merck & Co Inc (MRK) on Bullrun: valuation model: 59.5% overvalued, market cap USD 386.22B, P/E 125.0, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMRK
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal59.5% overvalued
- Market capUSD 386.22B
- P/E125.0
- Dividend yield2.3%
- Financial periodQ2 2026
- RevenueUSD 16.61B
- Net income-USD 1.34B
- Free cash flowUSD 4.48B
- Gross margin73.5%
Valuation Snapshot
Bullrun's latest valuation model marks Merck & Co Inc as 59.5% overvalued; latest market cap is USD 386.22B; P/E is 125.0; dividend yield is 2.3%.
Peer valuation comparison
Latest P/E is 125.05x versus a Healthcare sector median of 24.46x (411.2% above).
Latest dividend yield is 2.25% versus a Healthcare sector median of 2.11% (6.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 65.01B | USD 18.25B | USD 12.36B | 74.8% | 7.28 | USD 14.57B | USD 49.34B | USD 52.61B |
| FY2024 | USD 64.17B | USD 17.12B | USD 18.10B | 76.3% | 6.74 | USD 13.24B | USD 37.11B | USD 46.31B |
| FY2023 | USD 60.12B | USD 365.00M | USD 9.14B | 73.2% | 0.14 | USD 6.84B | USD 35.06B | USD 37.58B |
| FY2022 | USD 59.28B | USD 14.52B | USD 14.71B | 70.6% | 5.71 | USD 12.69B | USD 30.69B | USD 45.99B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 386.22B | 125.0 | 2.1% | 3.36 |
| 2025 | 2025-12-31 | USD 260.48B | 14.5 | 3.1% | 3.28 |
| 2024 | 2024-12-31 | USD 251.45B | 14.8 | 3.1% | 3.12 |
| 2023 | 2023-12-29 | USD 276.26B | 60.6 | 2.7% | 2.96 |
| 2022 | 2022-12-30 | USD 281.30B | 18.5 | 2.5% | 2.8 |
| 2021 | 2021-12-31 | USD 193.72B | 14.9 | 3.4% | 2.61 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.36 USD, yield 2.3%.
| Year | Dividends/share |
|---|---|
| FY2025 | 3.28 USD |
| FY2024 | 3.12 USD |
| FY2023 | 2.96 USD |
| FY2022 | 2.8 USD |
About Merck & Co Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Merck & Co Inc overvalued or undervalued?
Bullrun's valuation model currently marks Merck & Co Inc as 59.5% overvalued.
What is Merck & Co Inc's market cap?
Merck & Co Inc's market capitalization is USD 386.22B.
What is Merck & Co Inc's P/E ratio?
Merck & Co Inc's price-to-earnings (P/E) ratio is 125.0.
Does Merck & Co Inc pay a dividend?
Merck & Co Inc has a dividend yield of 2.3%.
What does Merck & Co Inc do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.